Interestingly, previous studies have shown that in high-grade sarcoma, patients who were NY-ESO-1 positive or MAGE-A4 positive had a significantly better overall survival rate than those who were negative for these two CTAs [18]. Here, MAGEA4 is linked to sarcoma.